Home >> Business >> Polymyositis Treatment Market Is Expected To Grow At A CAGR Of 5.9% From 2019 To 2027 | Credence Research

Polymyositis Treatment Market Is Expected To Grow At A CAGR Of 5.9% From 2019 To 2027 | Credence Research

According to the latest report published by Credence Research, Inc. “Polymyositis Treatment Market By Type Of Drug Class (Immunosuppressant, Alkylating Agent, Immunoglobulin, Monoclonal Antibodies, Corticosteroids) – Growth, Future Prospects And Competitive Landscape, 2019 – 2027,” the global polymyositis treatment market will significantly grow at a CAGR of 5.9% from 2019 to 2027.

Browse the full report at “Polymyositis Treatment Market

Market Insights

Polymyositis is a rare muscle disease which leads to chronic muscle inflammation coupled with muscle weakness. It is an autoimmune disorder mainly triggered by viral infection of connective tissue. Polymyositis is commonly observed in women than men and usually develops between in age group of 50 to 70 years; however, it’s not specific because it can affect people of any age or either sex. According to experts, the muscle weakness advances steadily over the course of a few weeks or months. In addition to that, the inflammation also tends to spread to several other areas of the body including the heart. The key factors responsible for growth of polymyositis treatment market are rising awareness and prevalence of polymyositis, and strong pipeline with around 5 promising molecules in phase III of clinical trials.

In 2018, immunosuppressant drug class is identified as the largest segment in polymyositis treatment market due to key factors assisting its growth such as it’s the most preferred treatment by medical practitioners, and immunosuppressant are also combined with corticosteroids to treat polymyositis effectively. In combination with corticosteroids are prescribed to decrease the side effects of corticosteroid treatment and enhance the effect of treatment. According to Orphanet, the reported annual incidence of polymyositis is between 1/250,000 and 1/130,000 new cases/year and prevalence 1/14,000.

Drug pipeline of polymyositis treatment is strong and comprises more than 10 molecules out of which 5 molecules are in phase III of clinical trials. The 5 molecules present in phase III of clinical trials are ustekinumab (Janssen Pharmaceutical), abatacept (Bristol-Myers Squibb), lenabasum (Corbus Pharmaceuticals Inc.), octagam 10% (Octapharma), and pirfenidone (Beijing Continent Pharmaceutical Co, Ltd.). Thus, in the near future polymyositis treatment market is expected to grow significantly throughout the forecast period from 2019 to 2027.

Download Free PDF Sample Request: Polymyositis Treatment Market

Market Competition Assessment:

The polymyositis treatment market is growing steadily and awareness associated with the disease is growing swiftly. However, the pipeline is strong and companies present in this market are working effectively on innovation and ground-breaking treatment. The key companies operating in the global polymyositis treatment market are Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG, and Genentech, Inc. among others.

Key Market Movements:

  • Increasing prevalence and awareness related to polymyositis & diagnosis expected to assist the market growth
  • Incessant demand for development of target-specific treatment for polymyositis
  • Rising diagnosis rate related to developed and developing countries will increase the need for effective polymyositis treatment market
  • Strong drug pipeline for polymyositis treatment around 5 molecules present in phase III of clinical trials and expected to assist the growth of the overall market in the near future
  • Being an orphan disease and complexities related to diagnosis and disease management initiative related to research & development activities are expected to aid the future market growth

By Type of Drug Class (2017–2027; US$ Mn)

  • Immunosuppressant
    • Methotrexate
    • Azathioprine
    • Cyclosporine
    • Tacrolimus
    • Mycophenolate
  • Alkylating Agent
    • Cyclophosphamide
    • Chlorambucil
  • Immunoglobulin
  • Monoclonal Antibodies
    • Rituximab
  • Corticosteroids
    • Prednisone

By Pipeline Analysis

  • Phase III (Sales till 2027; US$ Mn)
    • Ustekinumab 
    • Abatacept 
    • Lenabasum
    • Octagam 10%
    • Pirfenidone 
  • Phase I & II (Qualitative Information)
    • Tocilizumab (Phase II)
    • PF-06823859 (Phase II)
    • IFN-Kinoid (Phase II)
    • JBT-101 (Phase II)
    • Tofacitinib (Phase I)
    • VIB7734 (Phase I)

By Geography Segment (2017-2027; US$ Bn)

  • North America
  • Europe
  • Asia Pacific (APAC)
  • Middle East & Africa (MEA)
  • Latin America

Download Free PDF Sample Request: Polymyositis Treatment Market

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

Toll-Free (US/CANADA) Ph.: +1-800-361-8290

E-mail: sales@credenceresearch.com

Website: http://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *